Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the daily use of Rifapentine combined with Isoniazid to prevent tuberculosis in children under 13 years old, including those with and without HIV. This Phase III trial aims to find the appropriate dose of this combination taken once daily for 28 days. The study will include up to 144 children divided into two groups based on HIV status and will take place at multiple locations. Participants will receive the study drugs by oral dispersible tablets, grouped by weight into five categories. Children with HIV will also be assessed for their use of Dolutegravir as part of their antiretroviral therapy. The treatment period lasts 28 days, followed by a 24-week follow-up to monitor safety, tolerability, and drug levels in the blood. Both groups will be closely observed to assess how the drugs are processed in their bodies and any adverse effects. During the study, participants will have blood tests to measure drug concentrations and monitor liver, kidney, and blood cell function. Parent or guardian reports on treatment acceptability and adherence will be collected. Researchers will track adverse events throughout the treatment and follow-up periods. The total participation duration includes the initial 28-day dosing phase and subsequent 24 weeks of monitoring to ensure safety and effectiveness of the regimen.
Actively Recruiting
Healthy Volunteer
Researchers are investigating whether routine screening and treatment for two common sexually transmitted infections, chlamydia and gonorrhoea, during pregnancy can reduce the risk of preterm birth and other poor birth outcomes in Botswana. The study also assesses if this screening approach is affordable and cost-effective for the health system. Approximately 2,000 pregnant women attending their first antenatal care visit at several government clinics will be invited to participate. Participants will be randomly assigned to either receive routine antenatal care or additional screening and treatment for chlamydia and gonorrhoea during pregnancy. Participants in the intervention group will be screened for chlamydia and gonorrhoea using self-collected vaginal swabs at their first antenatal care visit and again in the third trimester between 28 and 32 weeks. Women who test positive will receive treatment following recommended guidelines, counseling on partner notification, and a test-of-cure about four weeks after treatment. The standard of care group will receive routine antenatal care, with urine specimens collected and tested retrospectively after delivery to assess infection prevalence. Both groups will undergo routine health checks, HIV and syphilis testing, ultrasounds, and other standard antenatal procedures. Throughout the study, participants will complete questionnaires about their health, socio-economic status, and pregnancy progress. Researchers will review medical records after birth to collect data on birth outcomes like preterm birth, birth weight, and maternal health conditions such as hypertension and preeclampsia. Study staff will support participant retention by providing reimbursements for time and travel and maintaining contact through multiple communication methods. The study will monitor outcomes until delivery and conduct detailed cost and cost-effectiveness analyses to evaluate the impact of screening and treatment on health and healthcare expenses.
Actively Recruiting
This research aims to evaluate the use of a lower INR target range 1.5 to 2.5 in patients who have a mechanical bileaflet heart valve implanted in the aortic position. The goal is to determine whether lowering the INR target can reduce bleeding risks without increasing the chance of blood clots or stroke. This study is important for patients who require lifelong warfarin treatment to prevent clot formation on their mechanical heart valves. Participants will be randomly assigned to one of two groups one group will have their warfarin dosing adjusted to maintain an INR target between 1.5 and 2.5, while the other group will follow the standard INR target range as currently recommended. Warfarin therapy is the main intervention, and the study compares these two INR target ranges to assess outcomes related to clotting and bleeding. Treatment and follow-up are expected to last about 2 to 3 years. Throughout the study, participants will be monitored for occurrences of thrombosis, thromboembolism, major and minor bleeding, strokes, heart attacks, and other complications. Researchers will track time spent in the therapeutic INR range and the incidence of extreme INR values. Safety and effectiveness assessments will continue through the study completion, which is anticipated to be approximately 2 to 3 years after enrollment.
Actively Recruiting
Healthy Volunteer
Chronic respiratory diseases such as chronic obstructive pulmonary disease COPD cause millions of deaths globally, with many occurring in low- and middle-income countries LMICs. These regions also have high rates of abnormal lung function, including restrictive spirometric pattern RSP, which can precede chronic respiratory diseases and is linked to overall mortality. Sub-Saharan Africa has a large population of people with HIV PWH, and HIV increases the risk of COPD and related deaths, though the mechanisms are not fully understood. This research involves a prospective cohort study in Botswana to describe patterns of abnormal lung function and explore how interactions between the body and microbiome relate to COPD and lung function decline in adults with and without HIV. The study aims to fill knowledge gaps by generating data from Batswana adults, a population disproportionately affected by COPD but underrepresented in research, thus supporting the development of more equitable COPD treatments. Participants aged 35 and older will be observed over five years with assessments including the Duke Activity Status Index DASI and the six-minute walk test to evaluate lung health and function. Data collection will include clinical evaluations, spirometry, and multi-omics analyses to understand host-microbiome relationships. The study involves regular monitoring and follow-up to assess respiratory health outcomes and activity status over time.
Actively Recruiting
Healthy Volunteer
Researchers are studying how long-acting injectable cabotegravir CAB-LA used for HIV pre-exposure prophylaxis PrEP interacts with hormonal contraceptive methods when used together in women. The study aims to understand if CAB-LA affects hormone levels and if hormonal contraceptives influence CAB-LA drug levels. This research is important because it explores options to improve prevention strategies for HIV and unintended pregnancies in women. Participants will be grouped based on their use of injectable contraceptive IM DMPA, etonogestrel implant, or no hormonal contraceptive, and whether they are using CAB-LA or not using PrEP. Study visits will occur every 4 to 12 weeks for up to 12 or 24 weeks after starting a contraceptive method. During these visits, blood samples will be collected to measure hormone concentrations and CAB-LA levels. The study also evaluates safety, side effects, satisfaction, and continuation of both CAB-LA PrEP and contraceptive methods. Women taking part will have blood samples taken at multiple time points, including immediately before scheduled CAB-LA injections and at weeks 0, 4, 8, 12, and 24 depending on their group. Researchers will assess hormone and drug levels, monitor for any adverse events, and collect data on participant satisfaction and continuation rates. Some participants may also share their experiences and decision-making in interviews up to 12 months after study participation. The total study duration varies by group but involves regular monitoring over several months.
Actively Recruiting
Researchers are evaluating an intervention aimed at supporting women living with both serious mental illness SMI and HIV in Botswana. These women face challenges with stigma that affect their adherence to psychiatric and antiretroviral treatments, which can worsen their health outcomes. The study tests a culturally tailored stigma reduction program called What Matters Most WMM during the critical transition from psychiatric hospitalization to outpatient care. The study also includes family members and policymakers to address stigma on multiple levels and encourage structural change. The trial has two main groups one receiving the WMM-based stigma intervention and another receiving an attention control focusing on general health education without stigma content. Women participants will attend eight group sessions led by a clinician and a peer with lived experience, starting during inpatient care and continuing in community settings after discharge. Family members will receive a parallel stigma intervention with three group sessions. Policymaker workshops will share findings through peer co-leaders to promote broader policy changes. Participants will be followed for four months after intervention completion, with assessments including viral load measurements, psychiatric and antiretroviral treatment adherence, mental health status, and social integration outcomes. Researchers will monitor changes from baseline to evaluate the interventions impact on viral suppression and related health factors. The study also tracks family stigma as a mechanism for change and includes safety monitoring throughout the study period, which is expected to last approximately 16 months from baseline to final follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a study in Botswana to see if offering testing for sexually transmitted infections STIs along with expanded HIV prevention options, specifically pre-exposure prophylaxis PrEP, helps more pregnant women start and continue using PrEP during pregnancy and after giving birth. The study involves 600 pregnant women without HIV who are seeking antenatal care. The purpose is to compare the usual care, which includes standard STI assessment without testing, to an approach that includes STI testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Participants are randomly assigned to one of two groups the intervention group receives STI testing using Xpert CTNG and TV assays during pregnancy and postpartum at three time points enrollment, 32 weeks gestation, and 9 months after delivery or two time points if enrolled in the third trimester. Women in this group learn to self-collect vaginal swabs. The standard care group receives STI symptom assessment per national guidelines during pregnancy and STI testing only at 9 months postpartum. All women are offered PrEP and can choose between oral pills or a dapivirine vaginal ring, with the option to start, stop, or switch methods at any time. Participants are followed through pregnancy and up to nine months after delivery. The study includes regular monitoring of PrEP use, including initiation, continued use, and adherence measured by drug levels in hair samples. Other assessments include STI rates, choice of PrEP method, birth outcomes, HIV incidence, quality of care, factors influencing adherence, and antimicrobial resistance. The total duration of participation includes antenatal care and postpartum follow-up visits.
Actively Recruiting
Researchers are evaluating adaptive strategies to improve the timely adoption of cervical cancer treatment in Botswana. This pragmatic trial uses a Sequential Multiple Assignment Randomized Trial SMART design to address patient- and system-level barriers such as delayed communication of results, challenges in accessing treatment, and poor coordination between referring clinics and cancer treatment centers. The strategies are based on behavioral economics principles and nudge techniques proven effective in preventive, HIV, and cancer care settings. The goal is to enhance coordination, communication, and navigation to increase timely treatment adoption in a scalable and sustainable way. Participants receive different combinations of outreach and reminder strategies. Initially, all receive direct clinic outreach to communicate when pathology results are ready. Those who do not attend the clinic within 30 days receive either asynchronous text message reminders alone or combined with telephone-based patient navigation. Some participants receive enhanced outreach, where both the clinic and patient are contacted directly, while others receive standard outreach. These adaptive strategies are tested in four experimental groups combining low-touch and high-touch reminder approaches. Throughout the study, participants attendance and treatment adoption are monitored, focusing on whether they receive treatment within 90 days of randomization. Researchers also assess the fidelity and reach of the interventions at 12 months. The study involves tracking communication effectiveness and care coordination through outreach and reminder methods. This trial is sponsored by the Abramson Cancer Center at Penn Medicine and runs from September 2023 to August 2027.